Latest / Deep Values: Value Investing Deep Dives / UnitedHealthGroup (UNH) Q3 2025 Financial Analysis
Transcript
- 0:00Welcome, everyone. Today, we're diving deep into a
- 0:02company that really impacts almost everyone in the US
- 0:05healthcare system. United Health Group, UNH.
- 0:09That's right. And this isn't just about
- 0:10healthcare delivery, is it? It's about a financial
- 0:12powerhouse. A true giant.
- 0:14Absolutely. And our source material today is
- 0:17quite interesting. It's a detailed financial
- 0:19research report and it even includes a, let's say, a Buffett
- 0:23style checklist applied directly to UNH.
- 0:26The classic value investing lens.
- 0:28Very useful. So our mission here really is to
- 0:32unpack this thing, understand UNHS complex business model,
- 0:37figure out what caused that recent stock price shock.
- 0:40Yeah, that sudden drop was pretty jarring.
- 0:42Right. And ultimately we want to see if
- 0:44this company, this, you know, well regarded compounder
- 0:47actually fits the bill. Now, is it a quality company
- 0:49trading at a fair price? Especially given that some major
- 0:52value investors made moves recently, did that crash create
- 0:56a real opportunity? That's the question.
- 0:58Exactly. So to kick things off, maybe we
- 1:00should talk about the structure because it's kind of unique.
- 1:02It really is. UNH isn't just one thing, it has
- 1:05this dual structure. It's vertically integrated payer
- 1:10and provider. Let's break that down.
- 1:11S 1st, you've got United Healthcare, UHC.
- 1:14That's the part most people probably think of the insurance
- 1:17arm. Yep, the core insurance
- 1:18business, that's where the bulk of the revenue comes from, maybe
- 1:217580%, mostly premiums. And they're huge.
- 1:25The report mentioned they added what, nearly 800,000 members
- 1:29year over year by Q 3/20/25. Massive scale, but the other
- 1:33piece, the arguably more strategic piece, is Optum.
- 1:37Right Optum. That's the health services side.
- 1:39Exactly. Think clinics, pharmacy benefit
- 1:41management, the PBM, data analytics, care delivery.
- 1:45It's huge in its own right. Optum Health serves something
- 1:48like 96,000,000 consumers. So it's not just about paying
- 1:51the bills, they're actually involved in delivering the care
- 1:54and managing costs through Optum.
- 1:56That's the key, that vertical integration, combining UHC, the
- 1:59payer, with Optum, the provider and service manager, that's
- 2:02their big advantage, or superpower, you might say.
- 2:04OK, so that structure sounds pretty solid, designed for
- 2:07stability maybe. But then Q32025 happened, ah.
- 2:12Yes, the plot twist. Revenue looked great, right up
- 2:1512% year over year over $113 billion, solid dot line.
- 2:20Fantastic top line, but the bottom line?
- 2:23That was a different story entirely.
- 2:25What happened there? Well, profitability just tanked.
- 2:27The net profit margin collapsed temporarily down to 2.1%, which
- 2:32is way down from like 6% the year before. 2% for a company
- 2:36like UNH? Wow.
- 2:37Yeah, Operating profit basically got cut in half.
- 2:40The market did not take it well. The stock got hammered.
- 2:43OK. So what caused such a dramatic
- 2:45margin squeeze for a company known for, you know, operational
- 2:49excellence? It really came down to 1 E
- 2:51metric, the medical care ratio, the MCR.
- 2:55That's the percentage of premiums they pay out in claims.
- 2:57Exactly. And historically UNH is really
- 2:59good at managing this. They usually keep it in the low
- 3:0180s, like 80 to 83%. That's their target zone.
- 3:04OK. But in Q32025 it's spiked jumped
- 3:07to about 4.7 percentage points, hitting almost 90 percent, 89.9%
- 3:11to be precisely. So nearly $0.90 of every dollar
- 3:13coming in as premium and went right back out the door as
- 3:16medical costs. Precisely.
- 3:18And when your target is 82 or $0.83, that jump just destroys
- 3:23your profit margin. What drove that jump?
- 3:26Was it just one thing? It was kind of a perfect storm
- 3:29really. 2 main things hit at once.
- 3:31First, you had higher utilization.
- 3:34Meaning people using more healthcare.
- 3:35Yeah, especially seniors, people who had maybe put off elective
- 3:38surgeries, think hips, knees during previous years were
- 3:42suddenly catching up. That pent up demand hit the
- 3:45system. OK, so more claims than
- 3:47expected. Right.
- 3:48And then at the same time, they got hit by new Medicare funding
- 3:51cuts and some other regulatory rate adjustments.
- 3:54So costs went up unexpectedly and reimbursement rates
- 3:57effectively went down. Squeeze from both sides.
- 4:00Ouch. So the argument in the source
- 4:02material then is that the market overreacted, mistook a temporary
- 4:06cyclical spike in costs for some kind of fundamental breakdown.
- 4:10That's the core thesis, yes, and the fact that management still
- 4:13slightly raised their full year outlook even amid that chaos
- 4:16suggests they see it as temporary too.
- 4:18They have confidence in the underlying business.
- 4:20Which brings us back to their competitive advantages, their
- 4:22Moat. Exactly, if they can weather
- 4:25that kind of storm, the Moat must be pretty strong.
- 4:28Let's talk about that. What makes it so formidable?
- 4:30Well, it's really two things we touched on scale and
- 4:33integration. The scale is just mind boggling,
- 4:36isn't it? Serving over 150 million people
- 4:38globally. It's immense.
- 4:40Think about the data they have, the negotiating power.
- 4:42The report mentions they touch roughly one in two Americans in
- 4:45some way. That gives them incredible
- 4:47leverage with hospitals, drug makers, doctors.
- 4:50Unmatched bargaining power, basically.
- 4:52Pretty much. And then there's the integration
- 4:54UHC plus Optum. How does that synergy play out
- 4:58in practice? Well, UHC sees all the claims
- 5:01data, right? They know where the costs are.
- 5:03Optum can then use that data to steer patients towards more
- 5:07efficient care, maybe lower cost settings, often clinics or
- 5:10services that optim itself runs. So it creates this kind of
- 5:13closed loop control costs, managed care capture savings.
- 5:17Exactly. It's a powerful feedback loop
- 5:19that competitors find really hard to replicate quickly.
- 5:23It takes years, decades, to build that kind of integrated
- 5:26system. And that efficiency, that Moat
- 5:29should show up in the numbers over time, right, Ignoring the
- 5:33Q3 blip? Oh absolutely.
- 5:35Their long term track record is stellar.
- 5:37Over the past decade, revenue grew about 12% a year.
- 5:40OK, strong growth. But crucially, net income grew
- 5:44even faster, around 15% annually.
- 5:47That shows operating leverage. And what about returns?
- 5:49How efficiently do they use capital?
- 5:52Very efficiently. Return on equity Roe
- 5:54consistently averages between 20 and 25%.
- 5:57That's well above what you typically consider a high
- 5:59quality benchmark, maybe 15%. That really speaks to the
- 6:03quality of the business and management.
- 6:05The sources also call UNH a cash machine.
- 6:08Why that specific term? Because they're free, cash flow
- 6:11generation is just incredibly strong and reliable.
- 6:14Free cash flow being the actual cash leftover after running the
- 6:16business and reinvesting. Exactly.
- 6:18The cash available for dividends, buybacks,
- 6:20acquisitions. UNH consistently generates FCF
- 6:23that's higher than its net income.
- 6:25Their FCF margin is typically 6 or 7% of revenue.
- 6:28And how does that compare? Well, a common benchmark, one
- 6:31often associated with Buffett, is looking for companies that
- 6:34can sustain A5 per seven FCF margin.
- 6:37UNH easily clears that in 2023 their FCF was $25.7 billion.
- 6:43Just a staggering amount of cash.
- 6:45OK, so a strong Moat, consistent high returns, massive cash flow.
- 6:50But that 2025 volatility is a reminder that things aren't
- 6:53always smooth sailing. Let's talk risks.
- 6:56Sure, there are definitely risks.
- 6:59If we assume that MCR spike was temporary, what are the more
- 7:02persistent headwinds or structural threats?
- 7:04You can sort of divide them. You have the shorter term
- 7:06cyclical things like those medical cost surges we just saw,
- 7:09they can happen again. Right.
- 7:11Healthcare utilization isn't perfectly predictable, no.
- 7:14And you also have ongoing regulatory risk, things like
- 7:17those Medicare Advantage rate adjustments, government policy
- 7:19changes can directly impact their earnings as Q3 showed.
- 7:22OK. That sound like manageable
- 7:24bumps, perhaps. What about the bigger, maybe
- 7:26existential risks, the kind that could fundamentally alter the
- 7:29business? The biggest one, the sort of
- 7:31Black Swan for the whole private insurance industry, is major
- 7:34healthcare policy reform. Like a Medicare for all
- 7:37scenario. Exactly.
- 7:38Or even a very aggressive public option that squeezes out private
- 7:42players. If something like that were ever
- 7:44implemented, it would drastically change or even
- 7:47eliminate the role of companies like UHC.
- 7:51The political likelihood waxes and wanes, but it's always out
- 7:55there as the ultimate tail risk. OK, what about competition,
- 8:00especially from tech? We see Amazon buying one,
- 8:03medical getting into pharmacy. Are these Big Tech players a
- 8:06threat? They are definitely a threat to
- 8:08parts of the business, particularly things like primary
- 8:10care delivery or pharmacy services, areas where Optum
- 8:13competes. Tech companies have capital
- 8:16reach, data, expertise. So they could chip away at
- 8:18Optim's growth. They could certainly try and
- 8:21they are applying pressure, but UNH is sheer scale, its existing
- 8:24relationships, the regulatory know how and that deep
- 8:27integration we talked about, that's a massive head start.
- 8:30Yeah, it's very hard to replicate the whole UNH
- 8:32ecosystem. So maybe less of an immediate
- 8:34existential threat, more of a long term competitive.
- 8:36Pressure, I think that's fair. The more immediate operational
- 8:39challenge, though, goes back to costs.
- 8:41Managing that MCR again. Always remember, the source
- 8:44notes noted that medical claims eat up about 83 cents of every
- 8:47premium dollar on average. That leaves very little room for
- 8:51error. So the entire profitability
- 8:53hinges on keeping that ratio under control.
- 8:56Pretty much, Optim's ability to actually bend the cost curve to
- 9:00deliver efficiencies and manage healthcare trends is absolutely
- 9:03critical for Unh's long term profit stability and growth.
- 9:07If they can't keep that MCR around their target 8283%, those
- 9:11nice net margins shrink fast. OK, that sets the stage nicely.
- 9:15We have this high quality complex business facing some
- 9:18real pressures. Let's put it through the ringer,
- 9:21the Buffett style checklist from the source material.
- 9:23Where does UNH shine all? Right.
- 9:25Well, on the quality and capital efficiency metrics, it passes
- 9:28with flying colors like free cash flow generation easily
- 9:31passes the 5% margin test return on retained earnings, the
- 9:35analysis showed it generates about 15% on the capital it
- 9:37reinvests, beating the typical 12% hurdle.
- 9:40And Roe? Absolutely passes.
- 9:42That average Roe of 2025% is way above the 15% quality threshold.
- 9:49Consistent growth in book value per share also passes.
- 9:52These all point to a high quality business with a strong
- 9:55Moat and effective management. OK, those are strong passes on
- 9:58quality, but the Buffett approach is famously price
- 10:01sensitive. Where does UNH usually stumble
- 10:04on valuation? Historically, it fails the
- 10:06simple PE ratio test. Buffett often looked for East
- 10:10ratios under 15 UNH because it's seen as such high quality and
- 10:14has consistent growth. Usually trades at a premium,
- 10:17maybe 17 to 22 times earnings. So the market typically
- 10:21recognizes its quality and prices it accordingly.
- 10:23Right. It also technically fails margin
- 10:25test. Gross margins around 2225% and
- 10:28net margins around 5-6 percent aren't high in an absolute
- 10:31sense, but that's just inherent to the insurance and healthcare
- 10:33services model. Doesn't mean it's a bad
- 10:35business, just a lower margin one than say a software company.
- 10:38So if it usually trades at a premium PE and has structurally
- 10:41lower margins, why would a classic value investor even look
- 10:44at it? Because you wait.
- 10:46You wait for moments of dislocation, moments of fear,
- 10:49like that Q3 MCR shock that temporarily pushed the price
- 10:52down into reasonable territory, even if it's not dirt cheap.
- 10:55And that leads us to the elephant in the room.
- 10:58Indeed, the ultimate validation Perhaps in Q22025, right around
- 11:03the time sediment was getting shaky, Warren Buffett's
- 11:06Berkshire Hathaway initiated a pretty substantial position.
- 11:09How substantial? Over 5 million shares, the
- 11:12estimated average cost, according to the source
- 11:14analysis, was likely somewhere between 280 and $300 per share.
- 11:18So Buffett and his team saw that dip as the opportunity The
- 11:22quality was high enough and the price briefly became good
- 11:24enough. That's the strong implication
- 11:27when arguably the world's most famous value investor steps in
- 11:30during a period of turmoil. For a company like UNH, it sends
- 11:33a powerful signal that maybe the market overreacted to short term
- 11:36issues. They likely saw the long term
- 11:39value proposition shine through the noise.
- 11:41OK, let's bring this home then. Let's talk about the specific
- 11:43valuation. The source material was written
- 11:45when the stock was trading around what, $370 a share?
- 11:48That's right. Around $370.
- 11:50That's right around $370 and it included a discounted cash flow
- 11:54or DCF analysis. The base case scenario assumed
- 11:58pretty reasonable growth going forward, right?
- 12:00High single digits. Yeah.
- 12:02The base case used assumptions like roughly 8% annual growth in
- 12:06free cash flow, which seems plausible given their track
- 12:09record and market position. So based on those assumptions,
- 12:12what did the DCF model suggest? UNH is intrinsic value.
- 12:16Actually was. The base case intrinsic value
- 12:18came out to approximately $570 per share.
- 12:21Wow. OK.
- 12:22So $370 market price versus a $570 estimated intrinsic value,
- 12:27that's a significant gap. It is.
- 12:29It represents a margin of safety of roughly 35%.
- 12:32And how does that compare to what value investors typically
- 12:34look for? Well, a common threshold is
- 12:36looking for at least to 25%, maybe 30% or more margin of
- 12:39safety. So $370 UNH was comfortably
- 12:43clearing that hurdle based on this base case analysis.
- 12:45So the. Conclusion from the analysis
- 12:46seems pretty clear. The Q3 shock created a temporary
- 12:50significant undervaluation in a very high quality company.
- 12:53That's the take away. A fundamentally strong,
- 12:56vertically integrated leader with a proven Moton cash
- 12:59generation was trading at a compelling discount thanks to
- 13:03short term market fears. For a long term investor focused
- 13:06on compounding, that's an attractive setup.
- 13:09So wrapping up, UNH appears to be a prime example of a high
- 13:12quality franchise that faced temporary headwinds pushing its
- 13:15stock price down to a level that even the most discerning value
- 13:18investors found attractive. Precisely.
- 13:20You get the quality, the Moat, the management, the cash flow,
- 13:24but at a discount, assuming of course that the Q3 issues were
- 13:28indeed temporary and not the start of a structural decline.
- 13:31Right. And that brings us to a final
- 13:33thought for you the listener. While the price might look
- 13:35right, UNH is long term Value creation really boils down to
- 13:39execution doesn't it? Specifically controlling those
- 13:42healthcare costs. Absolutely.
- 13:43It all comes back to managing that MC.
- 13:45So the question to ponder is, with an aging population using
- 13:49more services and drug prices continuing to rise, how
- 13:53efficient does that Optum division really need to be?
- 13:57Can they consistently keep that MCR near the historical 80 to
- 14:0183% target over the next decade to keep those profits
- 14:05compounding? That's the multibillion dollar
- 14:07question, isn't it? Optim's ability to innovate and
- 14:10execute on cost control is arguably the single most
- 14:12important factor for UNHS future growth.
- 14:14A fascinating challenge. Indeed.
- 14:17OK, that's all the time we have for this deep dive.
- 14:19Just a quick reminder before we go.
- 14:21All the analysis discussed today is based on publicly available
- 14:24sources and reflects the views in those sources.
- 14:26Interpretations can differ. This content is for educational
- 14:29purposes only and isn't investment advice.
- 14:32Please do your own research before making any investment
- 14:34decisions. That's right, always do your own
- 14:36homework. And if you enjoyed this
- 14:38discussion and want to hear more deep dives like this, you can
- 14:40subscribe to us on Apple Podcasts or Spotify.
- 14:42Just search for deep value investing.
- 14:44Thanks for listening.